Milukant – antiasthmatic means.

to Children from 2 to 5 years

• as additional treatment of bronchial asthma at patients aged from 2 up to 5 years with persistent asthma from easy to moderate severity it is insufficiently controlled by inhalation corticosteroids and also at insufficient clinical control of asthma by means of agonists of β-adrenoceptors of short.
instead of low doses of inhalation corticosteroids inhalation cannot apply
• As an alternative method of treatment to patients aged from 2 up to 5 years with persistent asthma of easy degree at which did not note the serious attacks of bronchial asthma demanding application of oral corticosteroids recently and also.
• Prevention of asthma at patients is more senior than 2 years at which the dominating component of asthma is the bronchospasm induced by physical activities.
• Relief of symptoms of seasonal and year-round allergic rhinitis.

Structure

• active ingredient: montelukast of sodium (montelukast sodium);
• 1 tablet contains montelukast of sodium of 4.16 mg in terms of montelukast of 4 mg;
• other components: microcrystalline cellulose, mannitol (E 421), krospovidon, ferrous oxide red (E 172), hydroxypropyl cellulose, dinatrium edetat, fragrance cherry, aspartame (E 951), talc, magnesium stearate.

Contraindication

Hypersensitivity to active agent or any excipient.

Children's age up to 2 years.

Side reactions

generally, Milukant is well transferred. At clinical trials the long-term treatment in different age groups shows the invariance of a profile of safety.

Infection and invasion: upper respiratory tract infections.

from blood and lymphatic systems: tendency to strengthening of bleeding, thrombocytopenia.

from the immune system of reaction of hypersensitivity, including an anaphylaxis, eosinophilic infiltration of a liver.

from mentality: violation of attention, a memory impairment, a sleep disorder, including nightmares, insomnia, a sleep-walking, irritability, anger, impatience, uneasiness, excitement, including agressive behavior or hostility, depressions, a tremor, is very rare – gallyu a disorientation, suicide thoughts and behavior (test of a suicide), a disfemiya, obsessivno-compulsive frustration.

Route of administration

children should use Drug under observation of adults. Tablets should be chewed before ingestion.

to Patients with asthma and allergic rhinitis (seasonal and year-round) needs to take 1 chewable tablet (4 mg) of 1 times a day. For relief of symptoms of allergic rhinitis time of reception should be selected individually.

For treatment of asthma the dose for children from 2 to 5 years makes 1 chewable tablet.

(4 mg) in day, in the evening. The Milukant it is necessary to accept in 1 hour prior to food or in 2 hours after a meal. There is no need for dose adjustment for this age group. The medicament Milukant in a dosage form of chewable tablet (4 mg) is not recommended for children 2 years are younger.

Feature of application

Use during pregnancy or feeding by a breast

Appointing Milukant to pregnant women, it is necessary to consider an advantage/risk ratio.

data on Milukant's penetration into breast milk nursing therefore it is necessary to consider a ratio advantage/risk when prescribing the medicine Milukant during feeding by a breast.

Children

Milukant, chewable tablets on 4 mg, it is intended for application to children aged from 2 up to 5 years.

Ability to influence speed of response at control of motor transport or other mechanisms

Usually Milukant does not affect ability to steer motor transport or other mechanisms, but seldom or never noted drowsiness or dizziness at the patients taking the medicament therefore during administration of medicament it is necessary to abstain from driving or other mechanisms.

Overdose

Specific information on treatment of overdose of montelukast. In researches of chronic asthma montelukast was appointed in doses to 200 mg/days to adult patients within 22 weeks, and at short-term researches – up to 900 mg/days within about 1 week clinically significant side reactions were absent.

At post-marketing application and clinical trials messages about sharp overdose, including messages of administration of medicament by the adult and to children in the dose exceeding 1000 mg arrived (about 61 mg/kg children have 42 months). In the majority of messages about cases of overdose no undesirable phenomena were observed. More often manifestations of side effects corresponded to a profile of safety of medicine and included: abdominal pain, drowsiness, thirst, headache, vomiting and psychomotor hyperactivity. Symptomatic treatment. It is unknown, montelukast at peritoneal dialysis or a hemodialysis is removed.

to Store

in original packing out of children's reach.